Drug Farm Signs Agreement with National Institutes of Health (NIH) to Develop Precision Targeted Treatment for ROSAH Syndrome

GUILFORD, Conn. & ROCKVILLE, Md.--(BUSINESS WIRE)--Drug Farm, a clinical-stage biopharmaceutical company developing innovative treatments targeting innate immunity, announced today the signing of a Cooperative Research and Development Agreement (CRADA) with the U.S. National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) to develop a precision targeted drug, DF-003 for the treatment of ROSAH (retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis an